Whilst CAR-T cells have been successful in hematological malignancies, the immunosuppressive tumor microenvironment and disparities in clinical trial access have limited their utility in solid tumors. Andras Heczey, MD, Baylor College of Medicine, Houston, TX, provides an overview of strategies to improve their efficacy in solid tumors, especially in liver cancer. The incorporation of interleukin-15 will help T cells proliferate in the hostile tumor microenvironment and CAR glypican-3 (GPC3) T cells have shown promising efficacy in preclinical studies. This interview took place at the 2022 San Antonio Liver Cancer Symposium (SALCS) in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
